Linked Life Data

17472616

Source:http://linkedlifedata.com/resource/pubmed/id/17472616

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-5-2
pubmed:abstractText
Recently, improved response and survival rates in patients treated with voriconazole and neurosurgery for central nervous system (CNS) aspergillosis have been reported. We assessed retrospectively the outcome in 17 patients with definite or probable CNS aspergillosis treated with amphotericin B alone (n = 15) or in combination with 5-fluorocytosine (n = 3) or itraconazole (n = 2). Four patients underwent neurosurgery. The mortality rate was 100% with a median survival of only 10 days (range: 3-60) after onset of first symptoms or first radiological evidence of CNS aspergillosis. In conclusion, treatment with amphotericin B and itraconazole has negligible efficacy in CNS aspergillosis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0933-7407
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
196-200
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
pubmed:affiliation
Medizinische Klinik III, Charité Campus Benjamin Franklin, Freie Universität, Berlin, Germany. stefan.schwartz@charite.de
pubmed:publicationType
Journal Article, Randomized Controlled Trial